0000950170-24-081631.txt : 20240703
0000950170-24-081631.hdr.sgml : 20240703
20240703171620
ACCESSION NUMBER: 0000950170-24-081631
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240701
FILED AS OF DATE: 20240703
DATE AS OF CHANGE: 20240703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lyon Joseph Douglas
CENTRAL INDEX KEY: 0001817838
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50679
FILM NUMBER: 241100928
MAIL ADDRESS:
STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED
STREET 2: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC
CENTRAL INDEX KEY: 0001088856
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770487658
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650.688.8803
MAIL ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
ownership.xml
4
X0508
4
2024-07-01
0001088856
CORCEPT THERAPEUTICS INC
CORT
0001817838
Lyon Joseph Douglas
C/O CORCEPT THERAPEUTICS INCORPORATED
149 COMMONWEALTH DRIVE
MENLO PARK
CA
94025
false
true
false
false
See Remarks
true
Common Stock
2024-07-01
4
M
false
5000
11.35
A
14290
D
Common Stock
2024-07-01
4
S
false
5000
32.4904
D
9290
D
Stock option (right to buy)
11.35
2024-07-01
4
M
false
5000
0.00
D
2029-02-08
Common Stock
5000
9167
D
Includes 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $32.49 to $32.70 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Fully exercisable.
Chief Accounting & Technology Officer
/s/ Joseph Douglas Lyon
2024-07-03